ArticleBioMed research international2017
Pharmacokinetics, Tissue Distribution, and Metabolism Study of Icariin in Rat.
Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Flavonoids in Nasal Therapeutics: Biological Activities, Delivery Challenges, and Formulation Strategies-A Systematic Review.Phytotherapy research : PTR · 2026Pooled it
- Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease.Journal of biochemical and molecular toxicology · 2026Review
- Role and therapeutic potential of icariin in metabolic diseases.Inflammopharmacology · 2026Review
- Review
- Icariin Modulates the Reproductive-Immune Axis: Molecular Insights and Therapeutic Potential.Current issues in molecular biology · 2026Review
- Hepatotoxicity Assessment of Anshenbunao Syrup by Multi-Component Quantification In Vivo/In Vitro and Cell Biological Evaluations.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A comprehensive narrative review ofJournal of pharmaceutical analysis · 2026Review
- Icariin Against Neurodegeneration: A Focus in Cell Death Pathways.International journal of molecular sciences · 2026Review
- Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment.Frontiers in pharmacology · 2026Review
- Multi-system Mechanisms in the Anti-osteoporotic Effects of Herbal Natural Products.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Traditional Chinese medicine regulating Wnt/β-catenin and OPG/RANKL/RANK pathways in osteoporosis: a narrative review based on bone coupling and pathological subtype differences.Frontiers in medicine · 2026Review
- Research Progress on Icariin Promoting Bone Injury Repair and Regeneration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Application of Natural Products in Neurodegenerative Diseases by Intranasal Administration: A Review.Pharmaceutics · 2025Review
- Article
- The therapeutic potential of icariin in the intervention of bone and joint diseases through multiple pathways: a narrative review.Frontiers in pharmacology · 2025Review
- Icariin as a Treatment Proposal in Mammalian Reproduction.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development and validation of UPLC-MS/MS method for icariin and its metabolites in mouse urine.Frontiers in pharmacology · 2024Article
- Nanotherapy for bone repair: milk-derived small extracellular vesicles delivery of icariin.Drug delivery · 2023Article
- Effects of Icariin and Its Metabolites on GPCR Regulation and MK-801-Induced Schizophrenia-Like Behaviors in Mice.Molecules (Basel, Switzerland) · 2023Article
- UPLC-MS/MS method for Icariin and metabolites in whole blood of C57 mice: development, validation, and pharmacokinetics study.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Icariin is one of the predominant flavonoids contained in Herba Epimedii (Yin-yang-huo in Chinese), a well-known Chinese medicine for the treatment of cancers and immune system diseases. Although Herba Epimedii has been widely used in China and there are so many and various research reports on the herbal drug and its main flavones, very limited data is available on the tissue distribution and biotransformation of icariin. In the present study, a liquid chromatographic method combined with electrospray ionization tandem mass spectrometry was developed to quantify the concentration of icariin in rat plasma and various tissues collected at different time points after oral administration of the total flavonoid extract of Herba Epimedii at a dose of 0.69 g/kg (corresponding to 42 mg/g icariin). Biological samples were processed by simple protein precipitation. Genistein was chosen as internal standard. The method was successfully applied to plasma pharmacokinetic and tissue distribution studies of icariin in rat. As a result, it was worth noting that the tissue distribution characteristics of icariin exhibited a significant gender difference. Moreover,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.